{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-098505","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.919023+00:00","generated_at":"2026-06-10T23:37:59.036614+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment","bullets":["Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.","Amendment to Japan license removes certain royalties and a $10M milestone but retains up to $45M in milestone payments.","Exclusive license covers 13 Asian markets including South Korea, Taiwan, Hong Kong, and Southeast Asian nations.","Maruho assumes Journey’s payment obligations to Dermira (Eli Lilly) for Territory sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-098505","json":"https://secwatch.observer/filing/0001104659-23-098505.json","markdown":"https://secwatch.observer/filing/0001104659-23-098505.md","text":"https://secwatch.observer/filing/0001104659-23-098505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/0001104659-23-098505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/tm2325553d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:37:59.036614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}